Innoviva Inc (INVA)

$20.80 -0.06 (-0.29%)
Market Cap 1.56B
Revenue (ttm) 358.71M
Net Income (ttm) 23.39M
EPS (ttm) N/A
PE Ratio 7.86
Forward PE 10.28
Profit Margin 6.52%
Debt to Equity Ratio 0.25
Volume 682,500
Avg Vol 817,474
Day's Range N/A - N/A
Shares Out 74.77M
Stochastic %K 21%
Beta 0.47
Analysts Sell
Price Target $32.25

Company Profile

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 238 9600
Address:
1350 Old Bayshore Highway, Suite 400, Burlingame, United States
Iightning
Iightning Dec. 5 at 4:53 AM
1ightning® Premium Options Alert (Actionable) Ticker: $INVA Contract: Dec 19 $20C Entry: 1.55 Exit: 2.92 Return: +88.68% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 4 at 10:40 PM
1ightning® Premium Options Alert (Actionable) Ticker: $INVA Contract: Dec 19 $20C Entry: 1.55 Exit: 2.92 Return: +88.68% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Lovelylatta
Lovelylatta Dec. 4 at 8:21 PM
$INVA added a few more.
0 · Reply
Iightning
Iightning Dec. 4 at 6:21 AM
1ightning® Premium Options Alert (Actionable) Ticker: $INVA Contract: Dec 19 $20C Entry: 1.58 Exit: 2.20 Return: +39.89% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Lovelylatta
Lovelylatta Dec. 4 at 12:20 AM
$INVA definitely about to fly 🕊️💸
0 · Reply
All4Retiring
All4Retiring Dec. 3 at 3:01 PM
$INVA
0 · Reply
All4Retiring
All4Retiring Dec. 3 at 2:37 PM
$INVA Please listen to the Piper Sandler conference INVA Q &A yesterday. First time I heard management discuss a partner to launch Zoliflodacin. https://investor.inva.com/presentations-events
0 · Reply
All4Retiring
All4Retiring Dec. 2 at 10:01 PM
$INVA
1 · Reply
All4Retiring
All4Retiring Dec. 2 at 9:59 PM
$INVA
0 · Reply
All4Retiring
All4Retiring Dec. 2 at 4:19 PM
$ALDX $INVA which has a PDUFA on 12/15 is down 2+% today.
0 · Reply
Latest News on INVA
Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference

Nov 25, 2025, 7:00 AM EST - 9 days ago

Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference

Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress

Nov 5, 2025, 4:05 PM EST - 4 weeks ago

Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress

Antheia Appoints Eric d'Esparbes as Chief Financial Officer

Oct 21, 2025, 8:00 AM EDT - 6 weeks ago

Antheia Appoints Eric d'Esparbes as Chief Financial Officer

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

Oct 20, 2025, 8:00 AM EDT - 6 weeks ago

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025

Oct 7, 2025, 8:00 AM EDT - 2 months ago

Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025

Innoviva, Inc. (INVA) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 2, 2025, 4:03 PM EDT - 3 months ago

Innoviva, Inc. (INVA) Presents At Citi's Biopharma Back To School Conference Transcript

Innoviva to Participate in Upcoming Investor Conferences

Aug 26, 2025, 7:00 AM EDT - 3 months ago

Innoviva to Participate in Upcoming Investor Conferences

Innoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

Aug 13, 2025, 8:00 AM EDT - 4 months ago

Innoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

Innoviva (INVA) Q2 Sales Jump 64%

Aug 6, 2025, 11:17 PM EDT - 4 months ago

Innoviva (INVA) Q2 Sales Jump 64%

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

Aug 6, 2025, 4:05 PM EDT - 4 months ago

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

Jun 12, 2025, 7:00 AM EDT - 6 months ago

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

Jun 10, 2025, 6:00 AM EDT - 6 months ago

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

May 20, 2025, 6:00 AM EDT - 7 months ago

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States

May 20, 2025, 1:15 AM EDT - 7 months ago

Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States

Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

May 7, 2025, 4:05 PM EDT - 7 months ago

Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

Mar 12, 2025, 5:08 PM EDT - 9 months ago

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

ARMP

Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

Mar 5, 2025, 7:00 AM EST - 9 months ago

Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

Feb 26, 2025, 4:04 PM EST - 10 months ago

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

Innoviva: Underappreciated Strength In Hospital Therapeutics

Feb 23, 2025, 1:11 AM EST - 10 months ago

Innoviva: Underappreciated Strength In Hospital Therapeutics

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 6, 2025, 7:00 AM EST - 10 months ago

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Dec 16, 2024, 7:00 AM EST - 1 year ago

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Dec 16, 2024, 1:15 AM EST - 1 year ago

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Nov 26, 2024, 7:00 AM EST - 1 year ago

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Innoviva to Participate in the UBS Global Healthcare Conference

Nov 12, 2024, 4:05 PM EST - 1 year ago

Innoviva to Participate in the UBS Global Healthcare Conference

Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

Nov 6, 2024, 4:05 PM EST - 1 year ago

Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024

Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs

Jun 18, 2024, 1:44 PM EDT - 1 year ago

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs

GSK

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

May 8, 2024, 4:05 PM EDT - 1 year ago

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

Innoviva to Participate in the BofA Securities Health Care Conference

May 8, 2024, 7:00 AM EDT - 1 year ago

Innoviva to Participate in the BofA Securities Health Care Conference

Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Apr 24, 2024, 7:00 AM EDT - 1 year ago

Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

Mar 4, 2024, 4:01 PM EST - 1 year ago

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

ARMP

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

Feb 29, 2024, 4:05 PM EST - 1 year ago

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

10 stocks you can bet on being inflation-proof

Feb 28, 2024, 2:48 PM EST - 1 year ago

10 stocks you can bet on being inflation-proof

AM CW CXW HCC OTTR PCAR RDN

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Nov 1, 2023, 4:15 PM EDT - 2 years ago

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Nov 1, 2023, 4:05 PM EDT - 2 years ago

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023

Innoviva: A Lot Of Moving Parts

Oct 9, 2023, 1:48 PM EDT - 2 years ago

Innoviva: A Lot Of Moving Parts

Innoviva to Participate in the Cantor Global Healthcare Conference

Sep 19, 2023, 8:30 AM EDT - 2 years ago

Innoviva to Participate in the Cantor Global Healthcare Conference

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

Sep 18, 2023, 8:00 AM EDT - 2 years ago

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

Innoviva Appoints Stephen Basso as Chief Financial Officer

Aug 25, 2023, 4:52 PM EDT - 2 years ago

Innoviva Appoints Stephen Basso as Chief Financial Officer

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Aug 2, 2023, 4:05 PM EDT - 2 years ago

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

Jul 11, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference

Jun 6, 2023, 4:05 PM EDT - 2 years ago

Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference

FDA approves Innoviva's bacterial pneumonia treatment

May 23, 2023, 10:32 PM EDT - 2 years ago

FDA approves Innoviva's bacterial pneumonia treatment

Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use

May 23, 2023, 6:42 PM EDT - 2 years ago

Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use

Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases

May 11, 2023, 6:45 PM EDT - 2 years ago

Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases

Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

May 9, 2023, 4:32 PM EDT - 2 years ago

Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

Iightning
Iightning Dec. 5 at 4:53 AM
1ightning® Premium Options Alert (Actionable) Ticker: $INVA Contract: Dec 19 $20C Entry: 1.55 Exit: 2.92 Return: +88.68% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 4 at 10:40 PM
1ightning® Premium Options Alert (Actionable) Ticker: $INVA Contract: Dec 19 $20C Entry: 1.55 Exit: 2.92 Return: +88.68% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Lovelylatta
Lovelylatta Dec. 4 at 8:21 PM
$INVA added a few more.
0 · Reply
Iightning
Iightning Dec. 4 at 6:21 AM
1ightning® Premium Options Alert (Actionable) Ticker: $INVA Contract: Dec 19 $20C Entry: 1.58 Exit: 2.20 Return: +39.89% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Lovelylatta
Lovelylatta Dec. 4 at 12:20 AM
$INVA definitely about to fly 🕊️💸
0 · Reply
All4Retiring
All4Retiring Dec. 3 at 3:01 PM
$INVA
0 · Reply
All4Retiring
All4Retiring Dec. 3 at 2:37 PM
$INVA Please listen to the Piper Sandler conference INVA Q &A yesterday. First time I heard management discuss a partner to launch Zoliflodacin. https://investor.inva.com/presentations-events
0 · Reply
All4Retiring
All4Retiring Dec. 2 at 10:01 PM
$INVA
1 · Reply
All4Retiring
All4Retiring Dec. 2 at 9:59 PM
$INVA
0 · Reply
All4Retiring
All4Retiring Dec. 2 at 4:19 PM
$ALDX $INVA which has a PDUFA on 12/15 is down 2+% today.
0 · Reply
Iightning
Iightning Dec. 2 at 12:38 AM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $INVA **Contract:** Dec 19 $22.5C **Entry:** 0.37 **Exit:** 0.51 **Return:** **+37.70% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
Iightning
Iightning Nov. 26 at 3:31 AM
1ightning® Options Trade Alert (Actionable) | Buy $INVA Dec 19 $22 Call | Enter: $0.51 Exit: $0.90 | Profit: 75.09% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 1:36 PM
1ightning® Options Trade Alert (Actionable) | Buy $INVA Dec 19 $22 Call | Enter: $0.51 Exit: $0.90 | Profit: 75.09% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 2:30 AM
1ightning® Options Trade Alert (Actionable) | Buy $INVA Dec 19 $22 Call | Enter: $0.51 Exit: $0.90 | Profit: 75.09% ROI | https://1ightning.com
0 · Reply
KirRoyalTrader
KirRoyalTrader Nov. 23 at 10:02 PM
$UVE $INVA $COLL $APPN
0 · Reply
Iightning
Iightning Nov. 21 at 11:45 PM
1ightning® Options Trade Alert (Actionable) | Buy $INVA Dec 19 $22 Call | Enter: $1.00 Exit: $1.80 | Profit: 80.58% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 21 at 3:05 AM
1ightning® Options Trade Alert (Actionable) | Buy $INVA Dec 19 $22 Call | Enter: $1.00 Exit: $1.80 | Profit: 80.58% ROI | https://1ightning.com
0 · Reply
History101
History101 Nov. 20 at 7:22 PM
$INVA 21.12!!
0 · Reply
Iightning
Iightning Nov. 20 at 12:28 AM
1ightning® Options Trade Alert (Actionable) | Buy $INVA Dec 19 $22 Call | Enter: $1.00 Exit: $1.80 | Profit: 80.58% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 19 at 8:43 AM
1ightning® Options Trade Alert (Actionable) | Buy $INVA Dec 19 $22 Call | Enter: $1.00 Exit: $1.80 | Profit: 80.58% ROI | https://1ightning.com
0 · Reply
ninergizer
ninergizer Nov. 18 at 5:07 PM
🧬 Biotech Catalyst Watchlist - The Winning Streak $ARWR's approved Plozasiran (formerly ARO-APOC3) Nov 18, 2025. My personal biotech DD list is now 3-for-3 on recent catalysts. 🔥 Adding $MIST and $INVA to the next set of tickers I'm watching closely. Your turn for DD. What catalysts are you watching? 👀 #Biotech #PDUFA #FDA #StocksToWatch #Trading
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 17 at 12:50 AM
$INSM $INVA $IONS $IRMD $ISRG
0 · Reply